The fact
This 'day-one' strategy pits innovative laboratories against generic manufacturers.
It raises questions about protecting innovation and access to healthcare.
Click the link to read an article on the topic:
This 'day-one' strategy pits innovative laboratories against generic manufacturers.
It raises questions about protecting innovation and access to healthcare.